Phase IIb data from the QUORUM study in heart failure (HF) patients will be presented at the European Society of Cardiology meeting, which will be held virtually from 27-30 August. If positive, we believe this data may be truly transformational for the company and we would expect partnership discussions to intensify with some of the global players in the cardiovascular space.Den vollständigen Artikel lesen ...